Savara (SVRA) Competitors

Savara (NASDAQ:SVRA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Is SVRA or MIRM more profitable?

Savara has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -31.69%. Mirum Pharmaceuticals' return on equity of -41.22% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-58.89%	-46.44%
Mirum Pharmaceuticals	-31.69%	-41.22%	-14.81%

Which has stronger earnings & valuation, SVRA or MIRM?

Savara has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$54.70M	-$0.47	-6.40
Mirum Pharmaceuticals	$336.89M	5.74	-$163.41M	-$1.85	-21.14

Do analysts prefer SVRA or MIRM?

Savara currently has a consensus price target of $8.83, suggesting a potential upside of 193.47%. Mirum Pharmaceuticals has a consensus price target of $58.20, suggesting a potential upside of 48.85%. Given Savara's higher possible upside, equities analysts plainly believe Savara is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Mirum Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09

Do institutionals & insiders hold more shares of SVRA or MIRM?

87.9% of Savara shares are held by institutional investors. 5.1% of Savara shares are held by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer SVRA or MIRM?

Savara received 169 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 75.86% of users gave Mirum Pharmaceuticals an outperform vote while only 66.89% of users gave Savara an outperform vote.

Company	Underperform	Outperform
Savara	Outperform Votes 301 66.89%	Underperform Votes 149 33.11%
Mirum Pharmaceuticals	Outperform Votes 132 75.86%	Underperform Votes 42 24.14%

Does the media refer more to SVRA or MIRM?

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Savara. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for Savara. Savara's average media sentiment score of 1.31 beat Mirum Pharmaceuticals' score of 1.05 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, SVRA or MIRM?

Savara has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

Summary

Mirum Pharmaceuticals beats Savara on 10 of the 18 factors compared between the two stocks.